Lantheus Holdings Inc (FRA:0L8)
€ 80.08 -20.93 (-19.61%) Market Cap: 5.64 Bil Enterprise Value: 5.41 Bil PE Ratio: 14.69 PB Ratio: 5.20 GF Score: 90/100

Lantheus Holdings Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript

Nov 12, 2019 / 10:35PM GMT
Release Date Price: €19.5 (+1.04%)
Erin Elizabeth Wilson Wright;dit Suisse AG
CrÃ;Research Division - Director & Senior Equity Research Analyst

© -

So hello, good afternoon, everybody. My name is Erin Wright. I cover life sciences tools, diagnostics at Credit Suisse.

We're happy to have Lantheus Holdings with us today. And with them, we have Mary Anne Heino, President and CEO; and in the audience, we also have Mark Kinarney as well, who heads up the IR effort. But I think I will hand it over to Mary Anne for a hopefully enlightening presentation.

Mary Anne Heino
Lantheus Holdings, Inc. - CEO, President & Director

Thank you, Erin. Good afternoon, everyone, and thank you for joining today.

Next slide, please. These are the statements that I am obliged to offer you today. I think it's particularly important to say because as part of my presentation today, I will speak to the transaction that we announced on October 1, our intention to acquire Progenics Pharmaceuticals. And so especially as I make comments about that today, I think the safe

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot